Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadramet and Velcade in Relapsed or Refractory Multiple Myeloma
NCT00478075Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Sep 2005
- Primary completion
- Nov 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, samarium-153 lexidronam in multiple myeloma (MM), sponsored by Mayo Clinic. Started Sep 2005; status: completed.
02
Drugs
bortezomibsamarium-153 lexidronam
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00478075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00478075.